Glycoconjugates and Glycomimetics as Microbial Anti-Adhesives

Trends in Biotechnology

Volumn 34, Issue 6, 2016, Pages 483-495

  Sattin, Sara ^a   Bernardi, Anna ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Adhesins; Anti adhesion therapy; DC SIGN; FimH; Lectins

Indexed keywords

ADHESION; CELL ADHESION; DISEASE CONTROL; PROTEINS;

ADHESINS; ANTIADHESION; DC SIGNS; FIMH; LECTINS;

CARBOHYDRATES;

BIOMATERIAL; CARBOHYDRATE DERIVATIVE; CD209 ANTIGEN; EPITOPE; GLYCOCONJUGATE; GLYCOMIMETIC; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BIOMIMETIC MATERIAL;

ENZYMATIC DEGRADATION; METABOLIC STABILITY; MICROBIAL ADHESION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; REVIEW; SYNTHESIS; UROPATHOGENIC ESCHERICHIA COLI; BACTERIUM ADHERENCE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; BIOMIMETIC MATERIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOCONJUGATES;

EID: 84957638374     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2016.01.004     Document Type: Review

References (80)

1. Sharon N., Lis H. Lectins as cell recognition molecules. Science 1989, 246:227-234.
2. Sharon N. Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim. Biophys. Acta 2006, 1760:527-537.
3. Imberty A., et al. Glycomimetics and glycodendrimers as high affinity microbial anti-adhesins. Chem. Eur. J. 2008, 14:7490-7499.
4. Bernardi A., et al. Multivalent glycoconjugates as anti-pathogenic agents. Chem. Soc. Rev. 2013, 42:4709-4727.
5. Pera N.P., Pieters R.J. Towards bacterial adhesion-based therapeutics and detection methods. MedChemComm 2014, 5:1027-1035.
6. Cecioni S., et al. Glycomimetics versus multivalent glycoconjugates for the design of high affinity lectin ligands. Chem. Rev. 2015, 115:525-561.
7. Firon N., et al. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect. Immun. 1987, 55:472-476.
8. Bouckaert J., et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol. Microbiol. 2005, 55:441-455.
9. Wellens A., et al. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex. PLoS ONE 2008, 3:e2040.
10. Vanwetswinkel S., et al. Study of the structural and dynamic effects in the FimH adhesin upon alpha-D-heptyl mannose binding. J. Med. Chem. 2014, 57:1416-1427.
11. Scharenberg M., et al. Target selectivity of FimH antagonists. J. Med. Chem. 2012, 55:9810-9816.
12. Fiege B., et al. The tyrosine gate of the bacterial lectin FimH: a conformational analysis by NMR spectroscopy and X-ray crystallography. ChemBioChem 2015, 16:1235-1246.
13. Sperling O., et al. Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH: design, synthesis and binding properties of mannoside ligands. Org. Biomol. Chem. 2006, 4:3913-3922.
14. Han Z., et al. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J. Med. Chem. 2010, 53:4779-4792.
15. Han Z., et al. Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J. Med. Chem. 2012, 55:3945-3959.
16. Klein T., et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J. Med. Chem. 2010, 53:8627-8641.
17. Jiang X., et al. Antiadhesion therapy for urinary tract infections - a balanced PK/PD profile proved to be key for success. J. Med. Chem. 2012, 55:4700-4713.
18. Kleeb S., et al. FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. J. Med. Chem. 2015, 58:2221-2239.
19. Gouin S.G., et al. Synthetic multimeric heptyl mannosides as potent antiadhesives of uropathogenic Escherichia coli. ChemMedChem 2009, 4:749-755.
20. Almant M., et al. Clustering of Escherichia coli type-1 fimbrial adhesins by using multimeric heptyl alpha-D-mannoside probes with a carbohydrate core. Chem. Eur. J. 2011, 17:10029-10038.
21. Bouckaert J., et al. Heptyl α-D-mannosides grafted on a β-cyclodextrin core to interfere with Escherichia coli adhesion: an in vivo multivalent effect. Chem. Eur. J. 2013, 19:7847-7855.
22. Lindhorst T.K., Dubber M. Octopus glycosides: multivalent molecular platforms for testing carbohydrate recognition and bacterial adhesion. Carbohydr. Res. 2015, 403:90-97.
23. Durka M., et al. The functional valency of dodecamannosylated fullerenes with Escherichia coli FimH - towards novel bacterial antiadhesives. Chem. Commun. 2011, 47:1321-1323.
24. Lindhorst T., et al. Inhibition of the type 1 fimbriae-mediated adhesion of Escherichia coli to erythrocytes by multiantennary α-mannosyl clusters: the effect of multivalency. Glycoconj. J. 1998, 15:605-613.
25. Yan X., et al. Glycopolymers as antiadhesives of E. coli strains inducing inflammatory bowel diseases. Biomacromolecules 2015, 16:1827-1836.
26. Lin C.C., et al. Selective binding of mannose-encapsulated gold nanoparticles to type 1 pili in Escherichia coli. J. Am. Chem. Soc. 2002, 124:3508-3509.
27. Hartmann M., et al. Saccharide-modified nanodiamond conjugates for the efficient detection and removal of pathogenic bacteria. Chem. Eur. J. 2012, 18:6485-6492.
28. Barras A., et al. Glycan-functionalized diamond nanoparticles as potent E. coli anti-adhesives. Nanoscale 2013, 5:2307-2316.
29. Khanal M., et al. Inhibition of type 1 fimbriae-mediated Escherichia coli adhesion and biofilm formation by trimeric cluster thiomannosides conjugated to diamond nanoparticles. Nanoscale 2015, 7:2325-2335.
30. Knight S., Bouckaert J. Structure, function, and assembly of type 1 fimbriae. Glycoscience and Microbial Adhesion 2009, 67-107. Springer, Berlin Heidelberg. T.K. Lindhorst, S. Oscarson (Eds.).
31. Arnault J.C. Surface modifications of nanodiamonds and current issues for their biomedical applications. Novel Aspects of Diamond 2015, 85-122. Springer International Publishing. N. Yang (Ed.).
32. Dondoni A., Marra A. Recent applications of thiol-ene coupling as a click process for glycoconjugation. Chem. Soc. Rev. 2012, 41:573-586.
33. Qi Z., et al. Multivalency at interfases: supramolecular carbohydrate-functionalized graphene derivatives for bacterial capture, release, and disinfection. Nano Lett. 2015, 15:6051-6057.
34. Brument S., et al. Thiazolylaminomannosides as potent antiadhesives of type 1 piliated Escherichia coli isolated from Crohn's disease patients. J. Med. Chem. 2013, 56:5395-5406.
35. Geijtenbeek T.B.H., et al. DC-SIGN, a dendritic cell apecific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597.
36. Geijtenbeek T.B.H., et al. Identification of DC-SIGN, a novel dendritic cell specific ICAM-3 receptor that supports primary immune responses. Cell 2000, 100:575-585.
37. Mitchell D.A., et al. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR: subunit organization and binding to multivalent ligands. J. Biol. Chem. 2001, 276:28939-28945.
38. van Kooyk Y., Geijtenbeek T.B. DC-SIGN: escape mechanism for pathogens. Nat. Rev. Immunol. 2003, 3:697-709.
39. Feinberg H., et al. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 2001, 294:2163-2166.
40. Guo Y., et al. Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat. Struct. Mol. Biol. 2004, 11:591-598.
41. Feinberg H., et al. Multiple modes of binding enhance the affinity of DC-SIGN for high mannose N-linked glycans found on viral glycoproteins. J. Biol. Chem. 2007, 282:4202-4209.
42. X complex. Biochemistry 2014, 53:5700-5709.
43. Anderluh M., et al. DC-SIGN antagonists, a potential new class of anti-infectives. Curr. Med. Chem. 2012, 19:992-1007.
44. Reina J.J., et al. HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors. Future Med. Chem. 2010, 2:1141-1159.
45. Lepenies B., et al. Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv. Drug Delver. Rev. 2013, 65:1271-1281.
46. Prost L.R., et al. Noncarbohydrate glycomimetics and glycoprotein surrogates as DC-SIGN antagonists and agonists. ACS Chem. Biol. 2012, 7:1603-1608.
47. Xiao L., et al. Antibody-mimetic ligand selected by mRNA display targets DC-SIGN for dendritic cell-directed antigen delivery. ACS Chem. Biol. 2013, 8:967-977.
48. Zhang Q., et al. Sequence-controlled multi-block glycopolymers to inhibit DC-SIGN-gp120 binding. Angew. Chem. Int. Ed. Engl. 2013, 52:4435-4439.
49. Carbohydrate Chemistry: State of the Art and Challenges for Drug Development 2015, Imperial College Press. L. Cipolla (Ed.).
50. Lederman M.M., et al. Topical application of entry inhibitors as 'virustats' to prevent sexual transmission of HIV infection. Retrovirology 2008, 5:116.
51. Garcia-Vallejo J.J., et al. Glycodendrimers prevent HIV transmission via DC-SIGN on dendritic cells. Int. Immunol. 2013, 25:221-233.
52. Gringhuis S.I., et al. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat. Immunol. 2009, 10:1081-1088.
53. Garcia-Vallejo J.J., van Kooyk Y. DC-SIGN: the strange case of Dr. Jekyll and Mr. Hyde. Immun. 2015, 42:983-985.
54. Mangold S.L., et al. Quinoxalinoneinhibitors of the lectin DC-SIGN. Chem. Sci. 2012, 3:772-777.
55. Lasala F., et al. Mannosyl glycodendritic structure inhibits DC-SIGN-mediated Ebola virus infection in cis and in trans. Antimicrob. Agents Chemother. 2003, 47:3970-3972.
56. Tabarani G., et al. Mannose hyperbranched dendritic polymers interact with clustered organization of DC-SIGN and inhibit gp120 binding. FEBS Lett. 2006, 580:2402-2408.
57. Luczkowiak J., et al. Glycofullerenes inhibit viral infection. Biomacromolecules 2013, 14:431-437.
58. Ribeiro-Viana R., et al. Virus-like glycodendrinanoparticles displaying quasi-equivalent nested polyvalency upon glycoprotein platforms potently block viral infection. Nat. Commun. 2012, 3:1303.
59. Kozlovska T.M., et al. Recombinant RNA phage Qβ capsid particles synthesized and self-assembled in Escherichia coli. Gene 1993, 137:133-137.
60. Chalker J.M., et al. A 'tag-and-modify' approach to site-selective protein modification. Acc. Chem. Res. 2011, 44:730-741.
61. Becer C.R., et al. High-affinity glycopolymer binding to human DC-SIGN and disruption of DC-SIGN interactions with HIV envelope glycoprotein. J. Am. Chem. Soc. 2010, 132:15130-15132.
62. Schaeffer E., et al. Dynamic micelles of mannoside glycolipids are more efficient than polymers for inhibiting HIV-1 trans-infection. Bioconjug. Chem. 2013, 24:1813-1823.
63. Wang S.K., et al. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3690-3695.
64. Martinez-Avila O., et al. Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 trans-infection of human T cells. ChemBioChem 2009, 10:1806-1809.
65. Garber K.C.A., et al. A general glycomimetic strategy yields non-carbohydrate inhibitors of DC-SIGN. Chem. Commun. 2010, 46:6747-6749.
66. Reina J.J., et al. 1,2-Mannobioside mimic: synthesis, DC-SIGN interaction by NMR and docking, and antiviral activity. ChemMedChem 2007, 2:1030-1036.
67. Thepaut M., et al. Structure of a glycomimetic ligand in the carbohydrate recognition domain of C-type lectin DC-SIGN. Structural requirements for selectivity and ligand design. J. Am. Chem. Soc. 2013, 135:2518-2529.
68. Sutkeviciute I., et al. Unique DC-SIGN clustering activity of a small glycomimetic: a lesson for ligand design. ACS Chem. Biol. 2014, 9:1377-1385.
69. Sattin S., et al. Inhibition of DC-SIGN-mediated HIV infection by a linear trimannoside mimic in a tetravalent presentation. ACS Chem. Biol. 2010, 5:301-312.
70. Berzi A., et al. A glycomimetic compound inhibits DC-SIGN-mediated HIV infection in cellular and cervical explant models. Aids 2012, 26:127-137.
71. Varga N., et al. Selective targeting of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) with mannose-based glycomimetics: synthesis and interaction studies of bis(benzylamide) derivatives of a pseudomannobioside. Chem. Eur. J. 2013, 19:4786-4797.
72. Varga N., et al. A multivalent inhibitor of the DC-SIGN dependent uptake of HIV-1 and Dengue virus. Biomaterials 2014, 35:4175-4184.
73. Berzi A., et al. Pseudo-mannosylated DC-SIGN ligands as potential adjuvants for HIV vaccines. Viruses 2014, 6:391-403.
74. Ordanini S., et al. Designing nanomolar antagonists of DC-SIGN-mediated HIV infection: ligand presentation using molecular rods. Chem. Commun. 2015, 51:3816-3819.
75. Andreini M., et al. Second generation of fucose-based DC-SIGN ligands: affinity improvement and specificity versus Langerin. Org. Biomol. Chem. 2011, 9:5778-5786.
76. Arosio D., et al. Effective targeting of DC-SIGN by alpha-fucosylamide functionalized gold nanoparticles. Bioconjug. Chem. 2014, 25:2244-2251.
77. Reymond J.L., et al. Glycopeptide dendrimers as Pseudomonas aeruginosa biofilm inhibitors. Chem. Soc. Rev. 2013, 42:4814-4822.
78. Boukerb A.M., et al. Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection. J. Med. Chem. 2014, 57:10275-10289.
79. Jarre G., et al. Playing the surface game - Diels-Alder reactions on diamond nanoparticles. Chem. Commun. 2011, 47:544-546.
80. Meinhardt T., et al. Pushing the functionality of diamond nanoparticles to new horizons: orthogonally functionalized nanodiamond using click chemistry. Adv. Funct. Mater. 2011, 21:494-500.